Hanall Biopharma (009420) - Total Liabilities
Based on the latest financial reports, Hanall Biopharma (009420) has total liabilities worth ₩44.17 Billion KRW (≈ $29.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hanall Biopharma long-term investment allocation to see how much of total assets are deployed in long-term investments.
Hanall Biopharma - Total Liabilities Trend (2011–2024)
This chart illustrates how Hanall Biopharma's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Hanall Biopharma total assets.
Hanall Biopharma Competitors by Total Liabilities
The table below lists competitors of Hanall Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Highlander Digital Technology Co Ltd
SHE:300065
|
China | CN¥788.01 Million |
|
Guangzhou Goaland Energy Conservation Tech Co Ltd
SHE:300499
|
China | CN¥985.08 Million |
|
CIE Automotive India Limited
NSE:CIEINDIA
|
India | Rs35.69 Billion |
|
Kinnevik Investment AB ser. B
ST:KINV-B
|
Sweden | Skr2.22 Billion |
|
Qingdao Haier Biomedical Co Ltd
SHG:688139
|
China | CN¥1.16 Billion |
|
AKSO HEALTH GR. (SPADR)/3
F:8HX
|
Germany | €13.73 Million |
|
Elvalhalcor Hellenic Copper and Aluminium Industry S.A
AT:ELHA
|
Greece | €1.42 Billion |
|
DXC Technology Co
NYSE:DXC
|
USA | $9.68 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Hanall Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Hanall Biopharma balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hanall Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hanall Biopharma (2011–2024)
The table below shows the annual total liabilities of Hanall Biopharma from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩44.53 Billion ≈ $30.18 Million |
-16.81% |
| 2023-12-31 | ₩53.53 Billion ≈ $36.28 Million |
+18.44% |
| 2022-12-31 | ₩45.19 Billion ≈ $30.63 Million |
+29.18% |
| 2021-12-31 | ₩34.99 Billion ≈ $23.71 Million |
-9.97% |
| 2020-12-31 | ₩38.86 Billion ≈ $26.33 Million |
-23.76% |
| 2019-12-31 | ₩50.97 Billion ≈ $34.54 Million |
+12.29% |
| 2018-12-31 | ₩45.39 Billion ≈ $30.76 Million |
-21.06% |
| 2017-12-31 | ₩57.50 Billion ≈ $38.97 Million |
+182.22% |
| 2016-12-31 | ₩20.37 Billion ≈ $13.81 Million |
-7.01% |
| 2015-12-31 | ₩21.91 Billion ≈ $14.85 Million |
-47.03% |
| 2014-12-31 | ₩41.36 Billion ≈ $28.03 Million |
+8.20% |
| 2013-12-31 | ₩38.23 Billion ≈ $25.90 Million |
-16.18% |
| 2012-12-31 | ₩45.60 Billion ≈ $30.91 Million |
-16.71% |
| 2011-12-31 | ₩54.75 Billion ≈ $37.11 Million |
-- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more